At a glance
ClinicalIndex Comparison RecordN/ACompleted· 34 enrolled
Drug / intervention
recombinant interferon alfa-2b +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of IFN-alpha-2b Dose Reduction With Dose Optimization
In Brief
A clinical study evaluating recombinant interferon alfa-2b and laboratory biomarker analysis for Stage IA Skin Melanoma and 8 related conditions. Completed, enrolled 34 participants across 1 site.
Detailed Summary
This pilot clinical trial studies recombinant interferon alfa-2b in treating patients with melanoma. Recombinant interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStage IA Skin Melanoma, Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
CountriesUnited States
CollaboratorsSchering-Plough
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedOct 2011
Primary CompletionJan 2014
TodayJul 2026
First PostedOct 27, 2011
Enrollment StartApr 22, 2008
Primary CompletionJan 5, 2014
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 14.7 years ago
Interventions
recombinant interferon alfa-2bbiological
Given SC
laboratory biomarker analysisother
Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.